Key statistics
On Monday, Shanghai Junshi Biosciences Co Ltd (8SJ:FRA) closed at 2.22, 62.04% above the 52 week low of 1.37 set on Feb 13, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.00 |
|---|---|
| High | 2.22 |
| Low | 2.22 |
| Bid | -- |
| Offer | -- |
| Previous close | 2.22 |
| Average volume | 333.33 |
|---|---|
| Shares outstanding | 1.03bn |
| Free float | 194.36m |
| P/E (TTM) | -- |
| Market cap | 36.22bn HKD |
| EPS (TTM) | -1.20 HKD |
Data delayed at least 15 minutes, as of Feb 09 2026 07:55 GMT.
More ▼
Announcements
- Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
- Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
- Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
- Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
- Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
- Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
- Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
- Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
- Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
More ▼
